We are live on ! Find out more
KAS

Kestra Advisory Services Portfolio holdings

AUM $31B
1-Year Est. Return 28.39%
This Fund
S&P 500
This Quarter Est. Return
-0.65%
1 Year Est. Return
+28.39%
3 Year Est. Return
+85.12%
5 Year Est. Return
+94.26%
10 Year Est. Return
AUM
$10B
AUM Growth
+$1.19B
Cap. Flow
+$1.34B
Cap. Flow %
13.35%
Top 10 Hldgs %
16.24%
Holding
2,211
New
217
Increased
1,290
Reduced
553
Closed
104

Sector Composition

Rank Sector Weight
1 Technology 10.3%
2 Financials 6.16%
3 Consumer Discretionary 5.18%
4 Healthcare 5.13%
5 Communication Services 4.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CDTX
2076
DELISTED
Cidara Therapeutics
CDTX
$68K ﹤0.01%
+1,525
New +$57.9K
LYG icon
2077
Lloyds Banking Group
LYG
$90.7B
$62K ﹤0.01%
25,460
+3,867
+18% +$9.47K
SRAX
2078
DELISTED
SRAX, Inc. Class A Common Stock
SRAX
$62K ﹤0.01%
11,600
-70
-0.6% -$336
MGF
2079
Aberdeen Government Markets Income Fund
MGF
$91.6M
$60K ﹤0.01%
+13,967
New +$61.6K
ARAY icon
2080
Accuray
ARAY
$33.9M
$57K ﹤0.01%
14,354
+364
+3% +$1.45K
MIN
2081
Aberdeen Intermediate Income Fund
MIN
$273M
$57K ﹤0.01%
+15,840
New +$58.5K
CCO icon
2082
Clear Channel Outdoor Holdings
CCO
$1.23B
$53K ﹤0.01%
19,500
+1,000
+5% +$2.5K
NAT icon
2083
Nordic American Tanker
NAT
$1.41B
$49K ﹤0.01%
19,121
+4,025
+27% +$10.1K
TONX
2084
TON Strategy Co
TONX
$175M
$45K ﹤0.01%
3
-1
-25% -$17K
CALA
2085
DELISTED
Calithera Biosciences, Inc
CALA
$44K ﹤0.01%
1,000
CIK
2086
Credit Suisse Asset Management Income Fund
CIK
$134M
$43K ﹤0.01%
12,372
-3,762
-23% -$13.1K
ATHX
2087
DELISTED
Athersys, Inc. Common Stock
ATHX
$41K ﹤0.01%
1,223
ATRS
2088
DELISTED
Antares Pharma, Inc.
ATRS
$41K ﹤0.01%
11,264
ABEV icon
2089
Ambev
ABEV
$48.2B
$40K ﹤0.01%
14,659
-517
-3% -$1.64K
COMS
2090
DELISTED
COMSovereign Holding Corp. Common Stock
COMS
$40K ﹤0.01%
250
SENS icon
2091
Senseonics Holdings Inc
SENS
$265M
$38K ﹤0.01%
+567
New +$38.5K
ATOS icon
2092
Atossa Therapeutics
ATOS
$21.8M
$34K ﹤0.01%
+700
New +$40.7K
ATXI
2093
DELISTED
Avenue Therapeutics, Inc. Common Stock
ATXI
$34K ﹤0.01%
+20
New +$41.3K
VEON icon
2094
VEON
VEON
$3.66B
$33K ﹤0.01%
632
MUX icon
2095
McEwen Inc
MUX
$1.06B
$31K ﹤0.01%
2,942
-163
-5% -$1.87K
RNTX
2096
Rein Therapeutics
RNTX
$65.7M
$31K ﹤0.01%
1,500
NINE
2097
DELISTED
Nine Energy Service
NINE
$27K ﹤0.01%
14,700
+4,000
+37% +$8.97K
KALA icon
2098
KALA BIO
KALA
$13.6M
$26K ﹤0.01%
4
CRBP icon
2099
Corbus Pharmaceuticals
CRBP
$168M
$24K ﹤0.01%
786
+66
+9% +$2.6K
NYMX
2100
DELISTED
Nymox Pharmaceutical Corp
NYMX
$24K ﹤0.01%
11,532

Similar funds

Kestra Advisory Services's Q3 2021 Portfolio in Review

As of Q3 2021, Kestra Advisory Services held 2,211 positions worth $10B, up 14% from $8.81B the previous quarter. Its ten largest holdings account for 16% of the portfolio.

Kestra Advisory Services deployed $1.34B of net new capital in Q3 2021, opening 217 new positions and adding to 1,290 existing holdings. Its largest new stake was ProShares Ultra S&P500: 519,172 shares worth $15.6M.

By sector, the portfolio is most concentrated in Technology at 10% of assets, down from 11% a quarter earlier, followed by Financials and Consumer Discretionary.

On the sell side, the largest reduction was iShares 1-5 Year Investment Grade Corporate Bond ETF, an estimated $18.6M trimmed.

  • Kestra Advisory Services's largest Q3 2021 buy was ProShares Ultra S&P500: 519,172 shares worth $15.6M.
  • Kestra Advisory Services added most to Vanguard Dividend Appreciation ETF in Q3 2021, an estimated $44.7M increase.
  • Kestra Advisory Services's biggest Q3 2021 reduction was iShares 1-5 Year Investment Grade Corporate Bond ETF, cutting an estimated $18.6M.
  • Kestra Advisory Services fully exited Old Republic International in Q3 2021, selling an estimated $3.03M.
  • Kestra Advisory Services's ten largest holdings make up 16% of its $10B portfolio in Q3 2021.
  • Kestra Advisory Services opened 217 new positions and closed 104 in Q3 2021.
  • Kestra Advisory Services's portfolio value rose 14% quarter-over-quarter to $10B.

Based on Kestra Advisory Services's 13F filing for Q3 2021, filed 19 Oct 2021.